258nok
-2,8 %
Date:2024-12-20Time:16:24:00Latest report:Q3-2024List:Oslo BorsTicker:ULTI
Market Cap:89 mnokEnterprise Value:-40 mnokNet Sales:- mnokEarnings:-149,3 mnokEmployees:0ISIN:NO0010851603

Ratios

10-year key figure history for Ultimovacs turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Ultimovacs with index and moving average MA50 and MA200.

Stockprice:2,58
MA50:2,03
MA200:5,16
Price/MA200:-50,1 %
RSI (14):63,2
Price/MA50:26,8 %

Description

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Pharmaceuticals